Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: An EORTC New Drug Development Group Study

Autor: Duffaud, F. *, Borner, M., Chollet, P., Vermorken, J.B., Bloch, J., Degardin, M., Rolland, F., Dittrich, C., Baron, B., Lacombe, D., Fumoleau, P.
Zdroj: In European Journal of Cancer 2004 40(18):2748-2752
Databáze: ScienceDirect
Externí odkaz: